Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Solid Tumors
This is an open-label study to evaluate the safety and efficacy of an anticancer medication (A01) with immune cells (IC01) in subjects with advanced solid tumors.
Advanced Solid Tumors
BIOLOGICAL: An anticancer medication (A01) and immune cells (IC01)
The adverse events associated with infusion of the anticancer medication or the immune cells will be assessed., Incidence and duration of all the adverse events will be recorded. The severity of adverse events will be evaluated according to NCI-CTCAE v4.03 criteria., Day 0 to 4 months after the end of the study
Tumor Response of the treatment in patients with advanced solid tumors., Response Evaluation Criteria in Solid Tumors (RECIST) from the NCI will be used for assessment of radiographic response., Before treatment and Day 28 to 4 months after the end of the treatment
This is an open-label study to evaluate the safety and efficacy of an anticancer medication (A01) with immune cells (IC01) in subjects with advanced solid tumors.